See more : NAVA HEALTH MD, LLC (NAVA) Income Statement Analysis – Financial Results
Complete financial analysis of Wuhan General Group (China), Inc. (WUHN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Wuhan General Group (China), Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Electric Power Development Co., Ltd. (9513.T) Income Statement Analysis – Financial Results
- Yodogawa Steel Works, Ltd. (5451.T) Income Statement Analysis – Financial Results
- NewHold Investment Corp. II (NHIC) Income Statement Analysis – Financial Results
- Avadh Sugar & Energy Limited (AVADHSUGAR.NS) Income Statement Analysis – Financial Results
- Atlas Crest Investment Corp. II (ACII) Income Statement Analysis – Financial Results
Wuhan General Group (China), Inc. (WUHN)
About Wuhan General Group (China), Inc.
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 14.18K | 33.28K | 0.00 |
| Cost of Revenue | 12.80K | 15.80K | 0.00 |
| Gross Profit | 1.38K | 17.47K | 0.00 |
| Gross Profit Ratio | 9.70% | 52.51% | 0.00% |
| Research & Development | 22.28K | 8.39K | 35.89K |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 1.66M | 129.58K | 143.73K |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.69M | 137.96K | 179.62K |
| Cost & Expenses | 1.70M | 153.77K | 179.62K |
| Interest Income | 201.00 | 3.00 | 0.00 |
| Interest Expense | 6.64K | 5.36K | 30.77K |
| Depreciation & Amortization | 4.15K | 206.30K | 171.86K |
| EBITDA | -1.70M | 415.36K | -179.62K |
| EBITDA Ratio | -12,010.84% | -362.09% | 0.00% |
| Operating Income | -1.68M | -120.49K | -179.62K |
| Operating Income Ratio | -11,882.90% | -362.09% | 0.00% |
| Total Other Income/Expenses | -28.92K | 530.49K | -30.77K |
| Income Before Tax | -1.71M | 410.00K | -210.39K |
| Income Before Tax Ratio | -12,086.93% | 1,232.11% | 0.00% |
| Income Tax Expense | -199.00 | 0.00 | 0.00 |
| Net Income | -1.71M | 410.00K | -210.39K |
| Net Income Ratio | -12,086.93% | 1,232.11% | 0.00% |
| EPS | -0.03 | 0.01 | 0.00 |
| EPS Diluted | -0.03 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 54.85M | 51.61M | 43.27M |
| Weighted Avg Shares Out (Dil) | 54.85M | 51.61M | 43.27M |
The Future Of Personalized Medicine For Mental Illness by Dr. Riyad Domingo
CAPE TOWN, SA / ACCESSWIRE / September 23, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: Newly...
Medspresso Announces Additional Speciality Coffees To The Range
CAPE TOWN, SA / ACCESSWIRE / September 17, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update:...
M2Bio Sciences Appoints Dr. Riyad Domingo as Chief Innovation Officer
CAPE TOWN, SA / ACCESSWIRE / September 2, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following remarkable update:...
Dr. AnnaRx(TM) Launching CBD & CBN Nutraceutical Line
CAPE TOWN, SA / ACCESSWIRE / August 24, 2021 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update: The...
Dr. Southey and Dr. Zarrebini Join M2Bio Sciences and Establish M2Bio Blockchain Research and Technology Group
CAPE TOWN, SA / ACCESSWIRE / August 19, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: WUHAN...
Wuhan General Group Launches M2Bio Labs in Hout Bay, South Africa
CAPE TOWN, SA / ACCESSWIRE / August 16, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update:...
Wuhan General Group Updates on Third Scientific Paper Published on Psychedelics
CAPE TOWN, SA / ACCESSWIRE / August 5, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update:...
Wuhan Sciences Launches the M2Bio Surfboard NFT Collection
CAPE TOWN, SA / ACCESSWIRE / June 29, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: M2Bio...
Wuhan General Group Appoints Robert "Black Tiger" Simbowe as Director of Health and Fitness
CAPE TOWN, SA / ACCESSWIRE / May 24, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: The...
Wuhan General Group Appoints Michael Sachar CEO of M2Bio Sciences Food & Beverage
CAPE TOWN, SA / ACCESSWIRE / May 20, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: The company...
Source: https://incomestatements.info
Category: Stock Reports